Also called: LL-37 , CAS: 154947-66-7, antimicrobial peptide, LL-37, human acetate, LL-37, human TFA
LL-37 is a natural germ-fighting substance that your own body makes. It is a tiny chain of building blocks called amino acids. It is part of your body's first line of defense against germs.
Scientists call it a host-defense peptide. LL-37 works by poking holes in the outer skins of bacteria and by calming swelling in the body. Research groups study it to learn how the body fights infections and helps wounds heal.
It is one of a small group of peptides studied for immune support. Most of the research so far comes from lab and animal studies, not large human trials. Scientists are still learning how safe and useful it might be in people. It is sold only as a research chemical and is not approved as a medicine.
Benefits
The main themes across 131 research studies, in plain language.
Evidence suggests LL-37 promotes wound healing by stimulating cell migration, proliferation, and the formation of new blood vessels.
Clinical studies suggest topical application of LL-37 may improve healing rates in chronic wounds, such as diabetic foot and venous leg ulcers.
Research points to LL-37 modulating immune responses by recruiting immune cells and regulating cytokines and chemokines.
Research confirms that Vitamin D3 upregulates the expression of LL-37, linking nutrient status to innate immune function.
Research suggests LL-37 acts as a broad-spectrum antimicrobial agent, targeting bacteria, fungi, and viruses through membrane disruption and direct killing mechanisms.
Studies indicate LL-37 can disrupt established bacterial biofilms and prevent new biofilm formation, potentially enhancing antibiotic efficacy.
Research indicates LL-37 exhibits antiviral effects against enveloped viruses, potentially by disrupting viral envelopes and triggering interferon responses.
Research highlights LL-37's potential for a lower risk of resistance development compared to traditional antibiotics, as well as synergy with existing drugs.
Research indicates LL-37 supports gut health by maintaining the integrity of the intestinal barrier and defending against pathogens.
Studies suggest LL-37 helps regulate inflammation, including neutralizing bacterial endotoxins and modulating inflammatory cytokines.
Evidence suggests LL-37 interacts with cell membranes and signaling pathways to support cellular defense mechanisms and reduce toxicity to host cells.
Studies suggest LL-37 stimulates the formation of new blood vessels, which is a key part of tissue repair and wound healing.
Preliminary research suggests LL-37 may offer neuroprotective effects through interactions with mitochondrial mechanisms.
Research suggests LL-37 may play a role in skin rejuvenation, including anti-aging, anti-wrinkle, and repair processes.
In vitro research suggests LL-37 may induce cell death in certain cancer cell lines, though effects appear context-dependent.
You just read the research on LL-37. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
LL-37 is the active 37-amino-acid fragment of the human cathelicidin antimicrobial peptide (CAMP gene) and a key effector of innate immunity. It directly kills bacteria and fungi at skin/mucosal/wound sites and modulates immunity (chemokine induction, TLR signaling, angiogenesis). It is an endogenous host-defense peptide; therapeutic analogs are in development but it is not an approved drug.
Evidence
Every claim above traces back to a source you can check — here are 10 of them.
The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung.
LL-37 | C205H340N60O53 | CID 16198951 - PubChem
Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial
Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial
Codelivery of 1α,25-dihydroxyvitamin D3 and CYP24A1 inhibitor VID400 by nanofiber dressings promotes endogenous antimicrobial peptide LL-37 induction
Human cathelicidin peptide LL-37 compacts nucleic acids and alters neutrophil extracellular trap structure
Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids
Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis
The Human Host-Defense Peptide Cathelicidin LL-37 is a Nanomolar Inhibitor of Amyloid Self-Assembly of Islet Amyloid Polypeptide (IAPP)
Evidence that the Human Innate Immune Peptide LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly
Timeline
Key moments in LL-37’s research and regulatory timeline — sourced and dated.
Wondering how LL-37 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.